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ABSTRACT:  
Acidosis is a key driver for many diseases, including cancer, sepsis, and neurological 
disorders. The spatiotemporal dynamics of dysregulated pH across different diseases 
remains elusive. Moreover, current diagnostic strategies are limited to urine and blood 
sampling, which do not provide specific localization of pH alterations in the body. We 
sought to explore if hydrophobic cyclic peptides that partition into the cellular membrane 
at low extracellular pH (denoted as “pHLIC”) can permit in vivo visualization of acidosis 
without the selective efficacy required for biomarker-based approaches.  
Methods: Acid-sensitive cyclic peptide c[E4W5C] pHLIC was conjugated to bifunctional 
maleimide-NO2A and radiolabeled with copper-64 (t½ = 12.7 h). Female C57BL/6J mice 
were administered an intraperitoneal injection of either LPS (15 mg/kg) or saline (vehicle) 
and serially imaged with [64Cu]Cu-c[E4W5C] (14-15 MBq) over 24 h. Ex vivo digital 
autoradiography was performed on resected left-hemisphere brain slices and 
subsequently stained with cresyl violet to enable high-resolution spatial analysis of tracer 
accumulation. A non- pH-sensitive cell-penetrating control peptide (R4W5C) was used to 
confirm specificity for acidosis in LPS-treated mice. CD11b (macrophage/microglia) and 
TMEM119 (microglia) immunostaining was performed in brain tissue to correlate levels 
of neuroinflammation with [64Cu]Cu-c[E4W5C] PET signal. 
Results: [64Cu]Cu-c[E4W5C] radiochemical yield and purity was >95% and >99% 
respectively, with molar activity >0.925 MBq/nmol. A significant (P < 0.001-0.05) increase 
in [64Cu]Cu-c[E4W5C] uptake was observed in LPS-treated mice (vs. vehicle) within 
peripheral tissues including blood, lungs, liver, and small intestines. Additionally, there 
was  significantly increased uptake of [64Cu]Cu-c[E4W5C] in the brain of LPS-treated 
  3 
animals. Autoradiographical analysis of brain slices confirmed increased uptake in the 
cerebellum, cortex, hippocampus, striatum, and hypothalamus of LPS-treated mice (vs. 
vehicle). This was also reflected in the IHC analysis, which demonstrated a quantitative 
increase in microglia/macrophage population in the hippocampal region (CD11b), along 
with qualitative increase in the hypothalamus (CD11b), cortex (both CD11b and 
TMEM119), and striatum (TMEM119). [64Cu]Cu-c[R4W5C] demonstrated significantly 
reduced uptake in the brain and periphery of LPS mice compared to our acid-mediated 
[64Cu]Cu-c[E4W5C] tracer. 
Conclusion: Here, we demonstrate for the first time that a pH-sensitive PET tracer 
detects acidosis in regions associated with sepsis-driven pro-inflammatory responses. 
This study suggests that [64Cu]Cu-pHLIC is a valuable tool to noninvasively assess 
acidosis associated with both central and peripheral innate immune activation. 
 
KEY WORDS: Acidosis, Neuroinflammation, Sepsis, pHLIC, Copper-64 
 
INTRODUCTION 
Maintenance of physiological pH is crucial for cellular homeostasis and is closely linked 
to innate immunological function (1, 2). When an acid-base imbalance occurs with blood 
and tissue pH becoming acidic – a condition known as acidosis – cellular and 
immunological dysfunction can occur, resulting in a life-threatening pathogenic state (3, 
4). Acidosis is one of the most common diagnoses seen in patients suffering from critical 
illness such as cardiovascular disease, diabetes, stroke, and sepsis, ultimately resulting 
in an overabundance of protons in the extracellular medium (5, 6-10). These  protons can 
interact with receptors on innate immune cells (e.g. neutrophils, monocytes, 
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macrophages and NK cells) to drive pro-inflammatory responses (5, 6). Both immune 
activation and suppression have been reported as a result of acidosis with low pH 
differentially affecting immune responses depending on cell type and pathways being 
investigated (1, 2, 6). 
Acute acidosis lasting from minutes to days is relatively common among critically 
ill patients (>50%) (7), whereas chronic acidosis ranging from weeks to years is less 
frequent (8). In the clinical setting, both acute and chronic acidosis can lead to significant 
cellular dysfunction in the periphery, along with neuronal damage and aberrant synaptic 
function centrally (9). This pH imbalance has been shown to modulate the immune 
response and trigger the release of proinflammatory cytokines, which can activate acid-
sensing ion channels (ASICs) in the periphery and brain (3, 10, 11). Pathologic acidosis 
and inflammation in peripheral tissues can trigger neuroinflammation and activate 
microglia in the CNS, implicating an important role for the crosstalk between ASICs and 
the immune system in neuroinflammatory diseases (1, 12). 
Efficient diagnosis and localization of acidosis has potential to greatly impact 
disease management and patient outcome (3, 13). The current method of diagnosing 
acidosis is via urine sampling (ketoacidosis) and/or arterial blood collection (4, 14). 
Although these methods provide information on the current physiological state, the latter 
is invasive and neither provides region-specific information regarding the pathologically 
affected tissues, hence accurate diagnosis and localization can be challenging (4, 15). 
Metabolic acidosis is a common clinical pathology that manifests in different ways 
affecting a breadth of tissues (8, 16), and can acutely affect the CNS (17). Since biopsies 
of the CNS are extremely invasive, there is an unmet need to noninvasively quantify 
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whole-body acidosis in vivo. Therefore, we sought to develop a probe to specifically 
detect acidosis with high sensitivity and identify whole-body acid-base alterations, 
allowing for more informed clinical decisions and disease management. 
Previously, we developed a novel class of molecules known as pH (Low) Insertion 
Peptides (pHLIPs®) that target acidity and utilize a mechanism that does not rely on the 
selective efficacy of other biomarker technologies (e.g. the need for target upregulation 
at a specific site of disease to delineate from non-target tissues) (18). The pHLIP family 
of peptides target acidity in the cellular microenvironment and have thus far shown utility 
in tumor imaging and delivery of therapeutic agents (19-21). The mechanism of pHLIP 
entails protonation of negatively-charged residues on a disordered linear peptide 
sequence in the acidic extracellular microenvironment, resulting in enhancement of 
peptide hydrophobicity and insertion into phospholipid bilayer of the cell membrane 
forming a stable transmembrane alpha helix (18). This pH-sensitive concept was 
leveraged to develop a novel class of cyclic peptides (pH (Low) Insertion Cycles, or 
pHLIC) for enhanced enzymatic stability versus linear peptides (22). These cyclic 
versions consist of negatively charged glutamate residues located at one side of the cycle 
and hydrophobic tryptophan residues on other (23). The glutamate residues are 
protonated at low extracellular pH to allow for better diffusion of pHLIC into membrane. 
When equilibrium is established, glutamate residues are de-protonated in cytoplasm 
preventing pHLIC from exiting the membrane and anchoring cycles into the lipid bilayer. 
Since pHLICs have promising properties for blood-brain barrier (BBB) penetration 
due to their inherent hydrophobic properties and reduced size compared to their linear 
pHLIP counterparts, we chose to explore a positron emission tomography (PET) labeled 
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version of a novel pHLIC peptide. We used pHLIC peptides for imaging of peripheral and 
central acidosis, taking advantage of both the quantitative nature of PET as well as the 
tracer principle of detecting changes in the acidic microenvironment. We selected the 
lipopolysaccharide (LPS)-induced mouse model of sepsis, as it is known to exhibit 
alterations in pH, extensive systemic inflammation, and subtle microglial activation in the 
brain (5, 6, 24, 25).  
The aims of this study were to investigate the utility of our novel pH-sensitive 
radiochemical probe, [64Cu]Cu-c[E4W5C] pHLIC, for tracking acidosis in LPS-versus 
saline-treated mice over the course of 24 h. The central hypothesis of this study was that 
pH-targeted cyclic peptide probe ([64Cu]Cu-c[E4W5C]) will successfully demarcate 
acidosis through PET and correlate with ex vivo brain uptake and macrophage/microglial 
activation. In order to confirm our probe’s specificity for the acidic microenvironment in 
this model, we included a [64Cu]Cu-c[R4W5C] probe as a negative control. Arginine 
residues (instead of glutamate in the pH-sensitive peptide) will create a cell-penetrating 
(26), but not via a pH-sensitive mechanism of insertion. 
We emphasize that it is not a facile process to take a biopsy of brain tissue. The 
innovation of this work lies in the ability to noninvasively collect a breadth of information 
about sepsis-induced acidosis in the whole-body and brain over time using our newly 
developed PET radiotracer to shed light on the complexities of acidosis. 
 
MATERIALS AND METHODS 
Materials. All materials use for synthesis and unless otherwise described, were 
purchased from Sigma-Aldrich (St. Louis, MO). 
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Synthesis of pHLIC-NO2A Construct. Peptides were designed and synthesized in the 
Andreev, Reshetnyak, and Parang labs using solid-phase peptide synthesis techniques. 
Structures and sequences of all peptides used, including NO2A conjugates and 
radioconstructs labelled with copper-64 are in Supplemental Fig. 1-4. Cyclic peptide 
c[E4W5C] or c[R4W5C] (1 mg, 0.6-0.65 mol) was mixed with 2× stoichiometric excess 
NO2A-maleimide (1.2-1.3 mol) in a 90:10 mixture of anhydrous dimethylformamide 
(DMF):degassed phosphate-buffered saline (PBS) for 2 h at 37 C. The conjugate was 
purified using C18 Preparative-HPLC with a 5-95% acetonitrile with 0.1% TFA over 40 min 
gradient (tR = 25 min) and evaluated using matrix assisted light desorption-ionization time-
of-flight mass spectrometry. Two additional peptides (another cyclic “pHLIC” variant and 
one linear “pHLIP”) were also conjugated to NO2A-maleimide using similar methods. Both 
pHLIC constructs were chosen for in vivo studies due to their favorable LogP value 
(Supplemental Table 1) for BBB penetration (27). Cyclic peptide c[E4W5C] proceeded 
further due to pilot experiments showing a more favorable BBB penetration, CNS 
biodistribution, and peripheral detection of acidosis in mice. Doses for animal experiments 
were diluted in PBS to a maximum concentration of 5% ethanol. 
Radiolabeling of pHLIC-NO2A. [64Cu]CuCl2 was obtained from University of Wisconsin 
Madison (Stanford) and the University of Washington St. Louis (MSK). Each experiment 
included [64Cu]CuCl2 controls to ensure reproducibility between experiments and 
institutions. pHLIC-NO2A (20 L, 16 nmol) was diluted in 0.1 M NH4Ac (pH 5.5). 
[64Cu]CuCl2 was added (14-15 MBq) and the reaction proceeded at 80 C, 800 rpm, for 
15 min. [64Cu]Cu-c[E4W5C] was purified with a C18 Sep Pak with 100% ethanol. Quality 
control was assessed using instant thin later chromatography using a 50 mM EDTA (pH 
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5) eluent. Partition coefficient experiments proceeded in a PBS:octanol mixture using 
previously reported techniques (28). Cold labeling of pHLIC-NO2A along with a 
description of the biophysical measurements of [natCu]Cu-c[E4W5C] and [natCu]Cu-
c[R4W5C] can be found in the Supplementary Materials. 
Animal models. All animal experiments were performed in accordance with the Stanford 
Administrative Panel on Laboratory Animal Care (APLAC), which is accredited by the 
Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC 
International) or the Institutional Animal Care and Use Committee at Memorial Sloan 
Kettering Cancer Center. Female C57BL/6J were ordered from Jackson Laboratories at 
6-8 weeks of age. LPS from Escherichia coli was ordered from Sigma-Aldrich and 
prepared in sterile saline at a concentration of 3 mg/kg. LPS was injected intraperitoneally 
(i.p.) 3 h prior to [64Cu]Cu-c[E4W5C] administration (15 mg/kg), and saline was used as a 
vehicle control. 
Biodistribution studies. Ex vivo gamma counting was performed to measure the uptake 
of the radioconjugate in tissues at 12 and 24 h post-radiotracer administration. Blood was 
collected via cardiac puncture prior to PBS perfusion. Brain and other tissues were 
harvested and weighed wet. The radioactivity within each organ was counted using a 
Hidex Automatic γ-counter. Tracer uptake expressed as percentage injected dose per 
gram (% ID/g) was calculated as the radioactivity associated with each tissue divided by 
the organ mass and the decay-corrected injected dose at the time of counting, as 
determined by a calibration curve established via serial dilution of the 64Cu-labelled 
peptide. 
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PET/CT Imaging. Radiotracer (16-20 nmol, 14-15 MBq in sterile PBS, 130-150 L) was 
injected intravenously and CT and 10 min static PET images were acquired at 1, 5, 9, 
and 20 h post-injection of radiotracer (4, 8, 12, and 24 h post-LPS inoculation) using a 
dual microPET/CT scanner (Inveon, Siemens). PET imaging time points with [64Cu]Cu-
pHLIC were adapted from a time course previously established by Demoin et al. (20). 
Brain PET quantitation was done using VivoQuant software (version 3.0, InviCRO) in 
accordance with procedures described by Chaney et al. (29).  
Autoradiography and Nissl staining. Ex vivo autoradiography was performed 
according to previously described methods (30) using 40 μm-thick left-hemisphere 
coronal brain sections collected at 12 and 24 h post-injection of [64Cu]Cu-c[E4W5C]. 
Anatomy of brain sections was confirmed by Nissl staining (cresyl violet acetate), using 
standard techniques. After exposing tissues to digital autoradiography films for 10 half-
lives, each film was scanned using a Typhoon phosphorimager. ImageJ software version 
2.0.0 was used to visualize images. 
Immunohistochemistry. For semiquantitative evaluation of activated microglia and 
inflammation, staining of CD11b and TMEM119 was performed on 5 m coronal brain 
sections, respectively, using previously described methods (30, 31).  
Statistical Considerations.  GraphPad Prism (version 7; GraphPad Software) was used 
for statistical analyses of the data. Biodistribution data were analyzed by the unpaired, 
two-tailed Student’s t-test and differences at the 95% confidence level. All other data were 
analyzed via 1-way or 2-way ANOVAs with multiple comparisons. P values of 0.05 or less 
were considered significant. 
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RESULTS 
Synthesis and Radiolabeling of pHLIC. Peptide-chelator conjugates c[E4W5C]-NO2A 
and c[R4W5C]-NO2A were produced in 55-60% yield with >99% purity. Further 
characterization was done using matrix-assisted light desorption time-of-flight (MALDI-
ToF) and/or liquid chromatography mass spectrometry (LCMS). MALDI-ToF results: 
c[E4W5C]-NO2A [M+H]+ = m/z: 1977.21 m/z; c[R4W5C]-NO2A [M+H]+ = m/z: 2085.11 m/z. 
LCMS results: [natCu]Cu-c[E4W5C] [M+5H]+ = m/z: 428.2 m/z; [natCu]Cu-c[R4W5C] 
[M+5H]+ = 446.7 m/z: m/z. Radiochemical yield and molar activity for all pHLIC conjugates 
were >95% and >0.925 MBq/nmol respectively. Radiochemical purity was >99% for all 
peptide conjugates (Supplemental Fig. 4), and [64Cu]Cu-c[E4W5C] was >90% stable in 
serum out to 48 h (Supplemental Fig. 5). Measured Log P values of [64Cu]Cu-c[E4W5C] 
were found to be 2.5  0.6 at pH 6 and 2.0  0.2 at pH 7.4 (n = 5 replicates per run; 3 
independent measurements) (Supplemental Table 1). 
In Vivo Study Design. Mice were administered 15 mg/kg LPS i.p to induce sepsis. The 
onset of acidosis has been reported to manifest peripherally as early as 4 h post-LPS 
injection, hence we chose this as our first time point to study the pharmacokinetics of our 
radiotracer (25). Microglial activation occurs within 24 h post-LPS administration in mice 
(12, 32). In order to study alterations in acidosis-induced inflammation in vivo over time, 
[64Cu]Cu-c[E4W5C] was injected 3 h post-LPS induction and serial static PET images were 
acquired at 1, 5, 9, and 21 h post-radiotracer injection (corresponding to 4, 8, 12, and 24 
h post-LPS induction). Fig. 1 illustrates this workflow along with the mechanism of pHLIC 
peptides’ interaction with membrane during acidotic conditions.  
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PET and Ex Vivo Biodistribution. Serial PET images acquired over the course of 24 h 
show a clear difference in peripheral [64Cu]Cu-c[E4W5C] uptake in vehicle vs. LPS-treated 
mice (Fig. 2) in tissues affected by acidosis. Supplemental Figs. 17 and 18 represents 
pilot data for [64Cu]Cu-[E5K]W5C PET, biodistribution, and dynamic PET. Less uptake and 
brain specificity was observed with [64Cu]Cu-[E5K]W5C vs. [64Cu]Cu-NO2A-c[E4W5C] 
PET, hence the rationale for moving forward with [64Cu]Cu-NO2A-c[E4W5C] for all 
subsequent studies. CT-guided quantitation of PET images demonstrated statistically 
significant increases in [64Cu]Cu-c[E4W5C] uptake in the kidneys, liver, lungs, and small 
intestine of LPS mice over 24 h (Fig. 2). Each of these selected tissues demonstrated 
significantly higher uptake of radiotracer in LPS mice at all time points except in kidneys 
at 4 h post-LPS injection. Full ex vivo biodistribution (for 12 and 24 h time points) is 
reported in Supplemental Table 2 and supports the in vivo findings (n = 4/group). PET 
quantitation of selected regions is represented in Supplemental Table 3 (n = 4/group). 
Zoomed in rescaled images show uptake of [64Cu]Cu-c[E4W5C] in the brain are 
represented in Fig. 3 for 12 and 24 h time points. Full brain atlas quantification, along with 
additional brain PET images at 4 and 8 h, including views in the frontal cortex and 
cerebellum for 12 and 24 h, can be found in Supplemental Figs. 7-10. Supplemental Fig. 
19 represents the brain atlas legend for the inVICRO PET quantification. A repeat cohort 
of [64Cu]Cu-c[E4W5C] was done in tandem with negative control tracer [64Cu]Cu-c[R4W5C] 
to highlight specificity of our pHLIC radtioracer for acidosis (Fig. 7). Full ex vivo 
quantification for these studies (brain and periphery) studies can be found in 
Supplemental Figs. 11-15 and Supplemental Tables 6-8. 
  12 
A statistically significant (P < 0.001-0.05) increase in [64Cu]Cu-c[E4W5C] uptake 
was observed in the brain of LPS-treated mice (vs. vehicle) in several regions, many of 
which have been reported to exhibit inflammation (cerebellum, cortex, hippocampus, 
hypothalamus, striatum, and midbrain) in this model (Fig. 3) (12, 33-36). Full PET 
quantitation (of all brain regions) can be found in Supplemental Table 4 for all time points. 
Autoradiography. Autoradiographical analysis of brain slices qualitatively confirmed 
increased uptake of the radiotracer in the cerebellum, cortex, hippocampus, and 
hypothalamus of LPS-treated mice (vs. vehicle) (Fig. 4). Many of these regions have been 
identified as key regions affected by neuroinflammation (12, 33). Marked signal was also 
observed in the choroid plexus and ventricles of both vehicle and LPS-treated mice. We 
repeated this cohort with to show a significant uptake of [64Cu]Cu-c[E4W5C] vs. negative 
control peptide [64Cu]Cu-c[R4W5C] in a number of key regions (Fig. 6). 
Immunohistochemistry. Immunohistochemical staining of CD11b and TMEM119 24 h 
post-LPS treatment show an increase in macrophage/microglia infiltration in the brain. A 
significant increase in number of CD11b+ cells (coupled with a more ameboid-like in 
morphology) in the hippocampal region of the brain was observed in LPS-treated mice 
compared to vehicle (Fig. 5). A qualitative increase of macrophage/microglia is also 
observed in the hypothalamus and cortex. A subtle increase in TMEM119 represents 
increased innate immune infiltration that is specific to microglia (36, 37) in the cortex and 
striatum (Supplemental Fig. 16). This data aligns with previous reports demonstrating 
increased neuroinflammation in the LPS model correlating to innate immune activation 
(5, 38, 39) and also mirrors the increased uptake of [64Cu]Cu-c[E4W5C] observed via PET 
and autoradiography in LPS-treated mice.  
  13 
DISCUSSION 
We report the first investigation of a pH-sensitive PET tracer for tracking acidosis in a 
murine model of sepsis. We have shown the potential of this tool to shed light on the 
connection between acidosis and innate immune activation over the course of 24 h during 
the onset of sepsis. Such a radiotracer could enable disease tracking not only in sepsis 
but in other disorders that exhibit clinical acidosis, including diabetes and stroke. Many 
groups are working to assess neuroinflammation noninvasively with PET, and the latest 
in this field is thoroughly reviewed by Narayanaswami et al. (40). Our study aims to 
identify acid-base imbalances in the periphery and the brain by targeting the acidic 
microenvironment, a specific danger signal in sepsis, and strengthen the connection 
between acidosis and neuroinflammation. 
Acidosis can be a life-threatening condition and is currently poorly understood with 
regard to whole-body progression, specific regional involvement, and interventions (4, 8). 
One approach being explored to assess the spatiotemporal dynamics of acidosis is 
Chemical Exchange Saturation Transfer (CEST) magnetic resonance imaging (MRI), and 
is well-described by Pagel and coworkers (41, 42). CEST-MRI exploits a specific MR 
frequency to generate an image while combining the specificity of magnetic resonance 
spectroscopy (MRS) with the spatial resolution of MRI (43). Recently, CEST-MRI is being 
investigated to improve analyses of tumor metabolism in the context of acidosis. 
Additionally, Longo and coworkers have combined CEST-MRI and [18F]FDG to explore 
the relationship between acidosis and hyperglycolysis within the tumor microenvironment 
(44) and found that there is a correlation between low extracellular pH and glucose 
uptake. We have observed a similar correlation with various pHLIP variants (unpublished 
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data). Additionally, several groups have paved the way for hyperpolarized MR for imaging 
metabolic acidosis, including for neuroinflammatory disorders (45, 46). However, 
hyperpolarized MR presents technical challenges for clinical translation due to its rapid 
decay in signal. Our pH-sensitive PET agent utilizes a single dose to assess acidosis and 
obtain dynamic information of a system in constant flux with ultra-high sensitivity. 
The most attractive application of pHLIP and pHLIC imaging platforms is the ability 
to target highly dynamic changes in the acidic microenvironment without needing to wait 
for slower changes in expression of a specific receptor. Relying on a probe to target a 
protein of interest can pose difficulties for clinical translation, especially when BBB 
penetration is desired (47). The design of our radiotracer includes a single point of 
conjugation, which does not affect the properties of its pH-targeting capabilities (23), 
which is futher evidenced by our biophysical measurements (Supplemental Fig. 6). Once 
acidosis has gone beyond peripheral damage to affect the CNS, it poses a much more 
challenging clinical situation (17), hence early and spatiotemporal detection is critical. 
Among the tested pHLIPs and pHLICs, c[E4W5C] showed the best BBB penetration and 
the highest sensitivity for detecting disease-associated alterations in pH, and was 
therefore selected for detailed investigation. In this study, we were able to exploit the 
sensitive, quantitative, and longitudinal characteristics of PET imaging to understand both 
the spatial and temporal dynamics of acidosis.  
The molecular mechanisms of how pH imbalance leads to cell damage are both 
diverse and complicated. Adversarial pH changes outside physiological norm can affect 
a number of biochemical systems, including cell development and degradation, energy 
metabolism, and neuronal function (e.g. metabolism of transmitter constituents) (8). There 
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have been studies that report the consequences of metabolic acidosis and how it affects 
tissues such as the liver, kidneys, and intestines (8, 53). ASICs are activated in the 
presence of inflammation, further perpetuating adverse immune responses, which can 
lead to significant neuroinflammation over the course of 24 h (12, 39). The utility of our 
pHLIC probe to not only detect systemic but also CNS inflammation makes this approach 
attractive for investigating pH alterations in a vast number of applications, including stroke 
and multiple sclerosis. These neurodegenerative diseases involve complex immune and 
acidotic processes in the brain and peripheral tissues (e.g. spleen, lymph nodes, 
intestines). The peripheral uptake of pHLIC in regions associated with acidosis in the LPS 
mouse model (e.g. lung, liver, kidneys, and small intestine) could be predictive of 
neuroinflammation and activation of microglia in the brain, which we observe as early as 
12 h. There are a number of novel therapeutics in the works that aim to treat metabolic 
acidosis and seek to target acid-sensing ion channels (48-52). We posit that our 
radiotracer would serve as a successful readout for these types of therapies to improve 
clinical outcomes of acidosis.  
 
CONCLUSION 
[64Cu]Cu-c[E4W5C] pHLIC is a valuable tool to noninvasively and longitudinally demarcate 
the spatiotemporal evolution of acidosis in LPS-induced sepsis. We believe that [64Cu]Cu-
c[E4W5C] has potential applications for other diseases tied to neuroinflammation and is 
currently being investigated. We expect that our pHLIC radiotracer will serve to increase 
understanding of the complex relationship between acidosis, immune function, and 
inflammation. 
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FIGURE 1. Schematic depicting general workflow to tracking acidosis and mechanism of 
membrane insertion. (A) LPS was injected i.p. into C57BL/6J mice and 64Cu-labelled 
pHLIC radiotracer was injected 3 h later. Mice underwent PET imaging at 4, 8, 12, and 
24 h post-LPS treatment. Autoradiography and immunohistochemistry were performed at 
12 and 24 h post-LPS treatment. (B) Mechanism of cyclic peptide insertion into the cellular 
membrane. pHLICs consist of negatively charged glutamate residues located at one side 
of the cycle and hydrophobic tryptophan residues on other side of the cycle. The 
glutamate residues are protonated at low extracellular pH to allow for better diffusion of 
pHLIC into membrane. When equilibrium is established, glutamate residues are de-
protonated in cytoplasm preventing pHLIC to exit out from the membrane and anchoring 
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cycles into the lipid bilayer. Pink circles represent glutamate residues, which become blue 
upon protonation as they insert into the membrane. Green circles represent tryptophan 
residues, and yellow circle is the cysteine residue, which is the point of conjugation the 
NO2A chelator to enable 64Cu-labeling. (C) Example protonation of glutamate residues in 
the acidic microenvironment.  
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FIGURE 2. [64Cu]Cu-c[E4W5C] pHLIC detects the presence and persistence of acidosis 
via serial PET imaging over the course of 24 h. (A) PET images of vehicle-treated animals 
vs. (B) LPS-treated mice at 4, 8, 12, and 24 h post-LPS injection. Peripheral quantitation 
of PET organs was performed by manually drawing regions of interest around select 
tissues at 4 h (C), 8 h (D), 12 h (E), and 24 h (F), post-LPS inoculation. Data is represented 
as average %ID/g ± SD with n = 4 animals/group. 
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FIGURE 3. [64Cu]Cu-c[E4W5C] pHLIC detects the presence and persistence of acidosis 
in the brain via PET imaging and 12 and 24 h. Coronal brain slices of [64Cu]Cu-c[E4W5C] 
PET and brain-atlas guided PET quantitation of vehicle vs. LPS-treated mice is 
represented. PET imaging of LPS-treated mice at 12 and 24 h are displayed side-by-side 
with vehicle-treated mouse brains, with corresponding brain atlas to indicate region. 
Respective quantitation of brain regions was achieved using VivoQuant and is shown at 
12 h (left) and 24 h (right). Data is represented as average %ID/g ± SD with n = 4 
animals/group. 
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FIGURE 4.  Autoradiography enables high-resolution [64Cu]Cu-c[E4W5C] pHLIC uptake 
in left-hemisphere brain slices. Brain slices exposed for autoradiography were stained 
with cresyl violet to correlate with Nissl bodies to highlight respective anatomy.  
Abbreviations on autoradiography/Nissl overlay: Cer: cerebellum; C: Cortex; HC: 
Hippocampus; Hth: Hypothalamus; BSt: brain stem; V: ventricle. Data is represented as 
average %ID/g ± SD with n = 3 animals/group. 
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FIGURE 5. Immunohistochemical analysis of CD11b staining identifies an increase of 
microglia/macrophages in select brain regions of LPS-treated compared to vehicle-
treated mice. Data is represented as average %ID/g ± SD with n = 3 animals/group. 
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FIGURE 6. Autoradiography enables high-resolution [64Cu]Cu-c[E4W5C] pHLIC (top) vs. 
[64Cu]Cu-c[R4W5C] control (bottom) uptake in right-hemisphere brain slices 24 h post-
LPS administration. Brain slices exposed for autoradiography were stained with cresyl 
violet to correlate with Nissl bodies to highlight respective anatomy.  Abbreviations on 
autoradiography/Nissl overlay: Cer: cerebellum; C: Cortex; HC: Hippocampus; Hth: 
Hypothalamus; Str: striatum. Data is represented n = 3 animals/group (vehicle) and n = 2 
animals/group (LPS). 
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FIGURE 7. Serial PET imaging of [64Cu]Cu-c[E4W5C] vs. [64Cu]Cu-c[R4W5C] (control) 
highlights the specificity of pHLIC for acidosis in LPS-induced acidosis over the course of 
12 h. Maximum intensity projections of [64Cu]Cu-c[R4W5C] show mainly clearance of the 
radiotracer with no difference between vehicle and LPS-treated mice. Maximum intensity 
projections of [64Cu]Cu-c[E4W5C] uptake represents small intestine, spleen, and kidneys, 
with a clear difference noted between vehicle and LPS-treated mice. Representative 
images selected from a pool of n = 4 animals/group. PET quantitation of peripheral tissues 
and brain signal can be found in the supplemental information. 
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KEY POINTS 
QUESTION: The central hypothesis of this study is that our pH low-insertion cyclic 
(pHLIC) peptide probe ([64Cu]Cu-c[E4W5C]) will successfully demarcate acidosis in a 
mouse model of sepsis in a manner that correlates with ex vivo brain uptake and 
microglial activation. 
PERTINENT FINDINGS: We demonstrate for the first time that a pH-sensitive PET tracer 
detects acidosis in regions associated with sepsis-driven pro-inflammatory responses. 
We observed significantly increased (P < 0.05) uptake of [64Cu]Cu-c[E4W5C] in the 
periphery and brain, which is mirrored by an increase in macrophage/microglial activation 
in these same regions.  
IMPLICATIONS FOR PATIENT CARE: Our study suggests that [64Cu]Cu-pHLIC is a 
valuable tool to noninvasively assess acidosis associated with both central and peripheral 
innate immune activation, and has potential to increase understanding of the dynamic 
relationship between acidosis and inflammation. 
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